46th Annual Healthcare Conference. We are absolutely delighted to have Merck senior leadership here with us today. Representing the company, Caroline Litchfield, who is Executive Vice President and ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Disclosed in the latest SEC filing, a significant insider purchase on January 28, involves Johannes Oosthuizen, President at Merck & Co (NYSE:MRK). What Happened: A Form 4 filing with the U.S.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.

Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining ...

Halozyme HALO-0.48%decrease; red down pointing triangle was granted a preliminary injunction that would prevent Merck MRK-0.02%decrease; red down pointing triangle & Co. from distributing a ...

Merck MRK2.18%increase; green up pointing triangle & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio ...

Merck & Co. logo displayed on the exterior of their research facility in San Francisco, Calif., on Sep. 21, 2020. This story was originally published on BioPharma Dive. To receive daily news and ...

Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines in the third quarter, adding to challenges the drugmaker is facing as it ...

Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...